Polynovo Ltd
ASX:PNV
Intrinsic Value
Polynovo Ltd. engages in the provision biodegradable medical devices. [ Read More ]
The intrinsic value of one PNV stock under the Base Case scenario is 0.63 AUD. Compared to the current market price of 2.12 AUD, Polynovo Ltd is Overvalued by 70%.
Valuation Backtest
Polynovo Ltd
Run backtest to discover the historical profit from buying and selling PNV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Polynovo Ltd
Current Assets | 70.3m |
Cash & Short-Term Investments | 45.6m |
Receivables | 15.5m |
Other Current Assets | 9.2m |
Non-Current Assets | 26.9m |
PP&E | 23.6m |
Intangibles | 1m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 14m |
Accounts Payable | 3.5m |
Accrued Liabilities | 1.9m |
Other Current Liabilities | 8.6m |
Non-Current Liabilities | 14.1m |
Long-Term Debt | 13.7m |
Other Non-Current Liabilities | 428k |
Earnings Waterfall
Polynovo Ltd
Revenue
|
84.7m
AUD
|
Cost of Revenue
|
-4.8m
AUD
|
Gross Profit
|
79.9m
AUD
|
Operating Expenses
|
-80.3m
AUD
|
Operating Income
|
-425.6k
AUD
|
Other Expenses
|
2m
AUD
|
Net Income
|
1.6m
AUD
|
Free Cash Flow Analysis
Polynovo Ltd
PNV Profitability Score
Profitability Due Diligence
Polynovo Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Polynovo Ltd's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
PNV Solvency Score
Solvency Due Diligence
Polynovo Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Polynovo Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PNV Price Targets Summary
Polynovo Ltd
According to Wall Street analysts, the average 1-year price target for PNV is 2.32 AUD with a low forecast of 2.02 AUD and a high forecast of 2.89 AUD.
Shareholder Return
PNV Price
Polynovo Ltd
Average Annual Return | 41.73% |
Standard Deviation of Annual Returns | 75.91% |
Max Drawdown | -78% |
Market Capitalization | 1.5B AUD |
Shares Outstanding | 690 233 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
Contact
IPO
Employees
Officers
The intrinsic value of one PNV stock under the Base Case scenario is 0.63 AUD.
Compared to the current market price of 2.12 AUD, Polynovo Ltd is Overvalued by 70%.